TCRT
NASDAQAlaunos Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$2.62-0.16 (-5.94%)
01:00 PM07:45 PM
News · 26 weeks35+125%
2026-04-262026-10-18
Mix1990d
- Insider10(53%)
- SEC Filings6(32%)
- Offering1(5%)
- Other1(5%)
- M&A1(5%)
Latest news
25 items- INSIDERSEC Form 3 filed by Alaunos Therapeutics Inc.3 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- PRAlaunos Therapeutics Announces Acquisition of Velaris TherapeuticsAcquisition of Velaris and concurrent oversubscribed $350 million private placement positions the Company to deliver multiple proof-of-concept datasets in pulmonary arterial hypertension Velaris Therapeutics, the ninth company launched based on Paragon-discovered assets, is advancing a pipeline built to address growth signaling imbalances that drive pulmonary vascular remodeling in PAH and secondary pulmonary hypertension (PH), including PH due to heart failure with preserved ejection fraction Velaris is developing a broad pipeline of ActRII-Fcs and an anti-PDGF-B antibody, designed to be developed as monotherapies or in combination, across cardiopulmonary indications The Company is expec
- SECSEC Form 8-K filed by Alaunos Therapeutics Inc.8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)
- PRParagon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc.Leadership team brings proven company-building and drug development experience to Paragon following $10.9 billion acquisition of Apogee by AbbVie Velaris is the ninth company launched around Paragon-discovered assets and the first supported by Paragon's expanded leadership teamBOSTON, Oct. 13, 2026 /PRNewswire/ -- Paragon Labs (together with related entities, "Paragon"), a biotechnology company focused on the discovery and development of differentiated biologics, today announced that members of the former senior leadership team of Apogee Therapeutics ("Apogee") have joined Paragon. The expanded leadership team will support Paragon-discovered assets through clinical development and help build
- SECSEC Form 8-K filed by Alaunos Therapeutics Inc.8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)
- INSIDERSEC Form 4 filed by Alaunos Therapeutics Inc.4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- INSIDERSEC Form 4 filed by Alaunos Therapeutics Inc.4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- INSIDERSEC Form 4 filed by Alaunos Therapeutics Inc.4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- INSIDERSEC Form 4 filed by Alaunos Therapeutics Inc.4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- SECAlaunos Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)
- SECSEC Form 424B3 filed by Alaunos Therapeutics Inc.424B3 - Alaunos Therapeutics, Inc. (0001107421) (Filer)
- PRAlaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rulesFORT LAUDERDALE, Fla., Sept. 18, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (NASDAQ:TCRT) today announced that it has entered into definitive agreements with institutional investors in a registered direct offering for the sale of 380,469 shares of its common stock and pre-funded warrants to purchase up to 386,654 shares of common stock at a price of $1.46 per share, for aggregate gross proceeds of approximately $1,120,000, before deducting placement agent fees and offering expenses. The offering was priced at-the-market under Nasdaq rules. The offering is expected to close on or about September 21, 2026, subject to the satisfaction of customary closing conditions. The Company int
- SECAlaunos Therapeutics Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)
- SECSEC Form 10-Q filed by Alaunos Therapeutics Inc.10-Q - Alaunos Therapeutics, Inc. (0001107421) (Filer)
- INSIDERCEO Weis Holger was granted 4,363 shares, increasing direct ownership by 21% to 25,483 units (SEC Form 4)4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- INSIDERDirector Jerman Michael Allen was granted 8,138 shares, increasing direct ownership by 52% to 23,759 units (SEC Form 4)4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- INSIDERDirector Vieser Jaime was granted 8,789 shares, increasing direct ownership by 23% to 47,642 units (SEC Form 4)4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- INSIDERDirector Postma Robert W was granted 8,463 shares, increasing direct ownership by 17% to 58,609 units (SEC Form 4)4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- INSIDERCEO Weis Holger was granted 4,568 shares, increasing direct ownership by 28% to 21,120 units (SEC Form 4)4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- SECSEC Form S-8 filed by Alaunos Therapeutics Inc.S-8 - Alaunos Therapeutics, Inc. (0001107421) (Filer)
- INSIDERChief Executive Officer Weis Holger was granted 3,880 shares, increasing direct ownership by 31% to 16,552 units (SEC Form 4)4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- PRAlaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse StudyThis statistical finding supports a lower liver-weight signal after adjustment for body fat percentage, suggesting the finding was not fully explained by measured body fat in this modelLiver-weight findings are directionally consistent with previously disclosed data on lower liver injury enzymes, lower NAFLD Activity Scores (NAS), lower HOMA-IR, an insulin-resistance-related biomarker, and favorable adipose endocrine signaling FORT LAUDERDALE, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Alaunos Therapeutics, Inc. (NASDAQ:TCRT), an early-stage biotechnology company developing novel therapeutics, today announced a new preclinical statistical analysis of liver weight adjusted for body fat percen
- SECAlaunos Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)
- INSIDERChief Executive Officer Weis Holger was granted 7,761 shares, increasing direct ownership by 158% to 12,672 units (SEC Form 4)4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
- INSIDERChief Executive Officer Weis Holger was granted 3,700 shares, increasing direct ownership by 306% to 4,911 units (SEC Form 4)4 - Alaunos Therapeutics, Inc. (0001107421) (Issuer)
TCRT FAQ
6 questionsWhat does Alaunos Therapeutics Inc. do?
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers; hunTR, a human neoantigen T-cell receptor platform; and mbIL-15 to treat solid tumors. Alaunos Therapeutics, Inc. has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The...Where does TCRT stock trade?
Alaunos Therapeutics Inc. (TCRT) is listed on NASDAQ.What sector and industry is TCRT in?
Alaunos Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about TCRT?
Alaunos Therapeutics Inc. has had 1 recent analyst action on file. The most recent action was from Wells Fargo: Overweight with a $300.00 price target on 2022-10-04. Recent price targets cluster around $300.00.What companies are similar to TCRT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare TCRT side-by-side with any of them on Quantisnow.How can I track TCRT on Quantisnow?
Quantisnow aggregates Alaunos Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TCRT to receive live email and push alerts on every new disclosure.